Display options
Cite
Gouma S, Weirick ME, Bolton MJ, et al. Sero-monitoring of health care workers reveals complex relationships between common coronavirus antibodies and SARS-CoV-2 severity. medRxiv. 2021;doi: 10.1101/2021.04.12.21255324.
Gouma, S., Weirick, M. E., Bolton, M. J., Arevalo, C. P., Goodwin, E. C., Anderson, E. M., McAllister, C. M., Christensen, S. R., Dunbar, D., Fiore, D., Brock, A., Weaver, J., Millar, J., DerOhannessian, S., Frank, I., Rader, D. J., Wherry, E. J., & Hensley, S. E. (2021). Sero-monitoring of health care workers reveals complex relationships between common coronavirus antibodies and SARS-CoV-2 severity. medRxiv : the preprint server for health sciences, . https://doi.org/10.1101/2021.04.12.21255324
Gouma, Sigrid, et al. "Sero-monitoring of health care workers reveals complex relationships between common coronavirus antibodies and SARS-CoV-2 severity." medRxiv : the preprint server for health sciences vol. (2021). doi: https://doi.org/10.1101/2021.04.12.21255324
Gouma S, Weirick ME, Bolton MJ, Arevalo CP, Goodwin EC, Anderson EM, McAllister CM, Christensen SR, Dunbar D, Fiore D, Brock A, Weaver J, Millar J, DerOhannessian S, Frank I, Rader DJ, Wherry EJ, Hensley SE. Sero-monitoring of health care workers reveals complex relationships between common coronavirus antibodies and SARS-CoV-2 severity. medRxiv. 2021 Apr 19; doi: 10.1101/2021.04.12.21255324. PMID: 33907765; PMCID: PMC8077588.
Copy Download .nbib Format: NLM
Share it on

medRxiv. 2021 Apr 19; doi: 10.1101/2021.04.12.21255324.

Sero-monitoring of health care workers reveals complex relationships between common coronavirus antibodies and SARS-CoV-2 severity.

medRxiv : the preprint server for health sciences

Sigrid Gouma, Madison E Weirick, Marcus J Bolton, Claudia P Arevalo, Eileen C Goodwin, Elizabeth M Anderson, Christopher M McAllister, Shannon R Christensen, Debora Dunbar, Danielle Fiore, Amanda Brock, JoEllen Weaver, John Millar, Stephanie DerOhannessian, Ian Frank, Daniel J Rader, E John Wherry, Scott E Hensley

Affiliations

  1. Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
  2. Division of Infectious Diseases, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
  3. Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
  4. Institute for Translational Medicine and Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
  5. Departments of Genetics and Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
  6. Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.

PMID: 33907765 PMCID: PMC8077588 DOI: 10.1101/2021.04.12.21255324

Abstract

Recent common coronavirus (CCV) infections are associated with reduced COVID-19 severity upon SARS-CoV-2 infection, however the immunological mechanisms involved are unknown. We completed serological assays using samples collected from health care workers to identify antibody types associated with SARS-CoV-2 protection and COVID-19 severity. Rare SARS-CoV-2 cross-reactive antibodies elicited by past CCV infections were not associated with protection; however, the duration of symptoms following SARS-CoV-2 infections was significantly reduced in individuals with higher common betacoronavirus (βCoV) antibody titers. Since antibody titers decline over time after CCV infections, individuals in our cohort with higher βCoV antibody titers were more likely recently infected with common βCoVs compared to individuals with lower antibody titers. Therefore, our data suggest that recent βCoV infections potentially limit the severity of SARS-CoV-2 infections through mechanisms that do not involve cross-reactive antibodies. Our data are consistent with the emerging hypothesis that cellular immune responses elicited by recent common βCoV infections transiently reduce disease severity following SARS-CoV-2 infections.

References

  1. Nature. 2020 Aug;584(7821):457-462 - PubMed
  2. Cell. 2020 Jun 25;181(7):1489-1501.e15 - PubMed
  3. JAMA Intern Med. 2020 Jul 21;: - PubMed
  4. Cell. 2021 Jan 7;184(1):169-183.e17 - PubMed
  5. Nat Med. 2020 Nov;26(11):1691-1693 - PubMed
  6. Science. 2020 Nov 27;370(6520): - PubMed
  7. Nat Med. 2021 Jan;27(1):78-85 - PubMed
  8. Nature. 2020 Nov;587(7833):270-274 - PubMed
  9. Nat Rev Immunol. 2020 Aug;20(8):457-458 - PubMed
  10. Cell. 2021 Apr 1;184(7):1858-1864.e10 - PubMed
  11. J Clin Virol. 2020 Jul;128:104437 - PubMed
  12. Science. 2020 Dec 11;370(6522):1339-1343 - PubMed
  13. J Clin Invest. 2021 Jan 4;131(1): - PubMed
  14. Sci Immunol. 2020 Jul 29;5(49): - PubMed
  15. Science. 2020 Oct 2;370(6512):89-94 - PubMed
  16. Science. 2020 Dec 4;370(6521):1227-1230 - PubMed
  17. Science. 2021 Feb 5;371(6529): - PubMed
  18. Nat Rev Immunol. 2020 Nov;20(11):709-713 - PubMed
  19. Nat Rev Microbiol. 2021 Mar;19(3):141-154 - PubMed
  20. JAMA. 2020 Jul 14;324(2):195-197 - PubMed
  21. J Infect Dis. 2021 Feb 3;223(2):197-205 - PubMed

Publication Types

Grant support